非小细胞肺癌患者EML4-ALK融合基因突变对个体化靶向治疗预后的影响  

Mutation and Significance of EML4-ALK Fusion Gene in NSCLC Patients

作　　者：白雪梅 郭炫[2] 赵新汉[2] 赵永华 BAI Xue-mei;GUO Xuan;ZHAO Xin-han(Hospital of Traditional Chinese Medicine of Yulin City,Shaanxi Province 719000)

机构地区：[1]陕西省榆林市中医医院检验科,陕西榆林719000 [2]西安交通大学第一附属医院,陕西西安710000 [3]西安交通大学第一附属医院长安区医院介入血管科,陕西西安710000

出　　处：《医学临床研究》2021年第10期1483-1485,1489,共4页Journal of Clinical Research

摘　　要：【目的】探讨非小细胞肺癌(NSCLC)患者棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)融合基因突变对个体化靶向治疗预后的影响。【方法】选取2016年2月至2018年2月不本院标保存的NSCLC组织标本110例,采用实时熒光定量PCR检测EML4-ALK融合基因突变情况,分析其对患者个体化靶向治疗预后的影响。【结果】共有13例患者检出EML4-ALK融合基因突变,突变率为11.82%(13/110)。其中年龄<60岁、TNM分期Ⅲ期患者EML4-ALK融合基因突变率分别为19.23%(10/52)和23.81%(10/42),明显高于年龄>60岁、Ⅰ〜Ⅱ期患者(P<0.05);EML4-ALK融合基因突变与未突变患者中位生存期分别为14.00个月(95%CI11.71〜16.29)和13.00个月(95%CI:12.39〜13.61),两组相比较差异无显著性(P>0.05)。【结论】NSCLC患者EML4-ALK融合基因突变与患者年龄、TNM分期有一定关系,但对个体化靶向治疗的预后无明显影响。【Objective】To investigate the mutation of echinoderms microtubule-associated protein-like 4-ana-plastic lymphoma kinase(EML4-ALK)fusion gene in patients with non-small cell lung cancer(NSCLC)and ex-plore its impact on the prognosis of individualized targeted therapy.【Methods】A total of 110 NSCLC tissue speci-mens preserved in our hospital from February 2016 to February 2018 were selected.The mutation of EML4-ALK fusion gene was detected by real-time fluorescence quantitative PCR.The effect of the mutation on individualized targeted therapy were analyzed.【Results】The mutation of EML4-ALK fusion gene was detected in 13 cases,the mutation rate was 11.82%(13/110).Of which,the mutation rates of EML4-ALK fusion gene were 19.23%and 23.81%in patients aged<60 years and TNM stage Ⅲ,respectively,which were significantly higher than those in patients aged≥60 years and stageⅠ〜Ⅱ(P<0.05);The median survival time of EML4-ALK fusion gene mutation and non-mutation patients was 14.00 months(95%CI:11.71-16.29)and 13.00 months(95%CI:12.39-13.61),there was no significant difference(P〉0.05).【Conclusion】The mutation of EML4-ALK fusion gene in NSCLC patients is related to patients age and TNM stage,while it has no significant effect on the prognosis of individualized targeted therapy.

关 键 词：癌 非小细胞肺 抗肿瘤药 基因 预后 

分 类 号：R734.2[医药卫生—肿瘤]